KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Cash from Operations (2018 - 2025)

Moderna (MRNA) has disclosed Cash from Operations for 8 consecutive years, with 930000000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Cash from Operations rose 12.73% to 930000000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was 1873000000.0, a 37.65% increase, with the full-year FY2025 number at 1873000000.0, up 37.65% from a year prior.
  • Cash from Operations was 930000000.0 for Q4 2025 at Moderna, up from 847000000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 4063000000.0 in Q2 2021 to a low of 1600000000.0 in Q3 2023.
  • A 5-year average of 530300000.0 and a median of 278000000.0 in 2022 define the central range for Cash from Operations.
  • Peak YoY movement for Cash from Operations: skyrocketed 17029.17% in 2021, then tumbled 734.92% in 2023.
  • Moderna's Cash from Operations stood at 3310000000.0 in 2021, then tumbled by 49.79% to 1662000000.0 in 2022, then tumbled by 62.58% to 622000000.0 in 2023, then skyrocketed by 32.64% to 825000000.0 in 2024, then grew by 12.73% to 930000000.0 in 2025.
  • Per Business Quant, the three most recent readings for MRNA's Cash from Operations are 930000000.0 (Q4 2025), 847000000.0 (Q3 2025), and 919000000.0 (Q2 2025).